Resultados de Búsqueda
Ceritinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)‑positive advanced non-small-cell lung cancer in adults, only if the company ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Most people with untreated ALK‑positive advanced non-small-cell lung cancer are offered crizotinib. Chemotherapy may be offered if the person's ALK mutation status isn't known, and therefore is not a relevant comparator for ceritinib. There are no trials directly comparing ceritinib with crizotinib; the clinical trial compares ceritinib with chemotherapy. Because the clinical trial has not finished, it is unable to show how much ceritinib prolongs life compared with chemotherapy. But it ...
ver más ... 2018Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless MRI is contraindicated.
NICE
National Institute for Health and Clinical Excellence (NICE)
Refer people with a suspected glioma to a specialist multidisciplinary team at first radiological diagnosis for management of their tumour. Consider advanced MRI techniques, such as MR perfusion and MR spectroscopy, to assess the potential of a high-grade transformation in a tumour appearing to be low grade on standard structural MRI. The evidence indicated that standard structural MRI is useful in distinguishing high-grade from low-grade glioma. The committee noted that this knowledge will ...
ver más ... 2018Lenvatinib is recommended as an option for untreated, advanced, unresectable hepatocellular carcinoma in adults, only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with lenvatinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Advanced unresectable hepatocellular carcinoma is treated with sorafenib, but some people cannot tolerate it because of side ...
ver más ... 2018Selective internal radiation therapy (SIRT) is not recommended as a human therapy, it can only be used in the context of research. Current evidence on the safety of SIRT for unresectable primary ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Further research in the form of prospective studies, including randomised controlled trials, should address patient selection, quality-of-life outcomes and overall survival. Patient selection for the research studies should be done by a multidisciplinary team. The procedure should only be done in specialist centres by clinicians trained and experienced in managing cholangiocarcinoma. Clinicians should enter details about all patients having SIRT for unresectable primary intrahepatic ...
ver más ... 2018It's recommended FDG PET-CT to guide management for people treated with radical chemoradiotherapy who have an oropharyngeal primary cancer site and 2 or more positive nodes in the neck, all of which ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Consider FDG PET-CT to guide management for people treated with radical chemoradiotherapy who have an oropharyngeal primary site with 1 positive node in the neck that is less than 6 cm across, or an oropharyngeal primary site with 1 or more positive nodes larger than 6 cm across in the neck or a hypopharyngeal or laryngeal primary site with 1 or more positive nodes in the neck. For people having an FDG PET-CT scan after chemoradiotherapy, perform the scan 3 to 6 months after chemoradiotherapy ...
ver más ... 2018